INVENTIVA SA (6IV.DE) Fundamental Analysis & Valuation

FRA:6IV • FR0013233012

Current stock price

4.77 EUR
+0.14 (+3.14%)
Last:

This 6IV.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. 6IV.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 6IV has reported negative net income.
  • 6IV had negative earnings in each of the past 5 years.
  • In the past 5 years 6IV always reported negative operating cash flow.
6IV.DE Yearly Net Income VS EBIT VS OCF VS FCF6IV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -197.89%, 6IV is doing worse than 87.65% of the companies in the same industry.
Industry RankSector Rank
ROA -197.89%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
6IV.DE Yearly ROA, ROE, ROIC6IV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for 6IV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
6IV.DE Yearly Profit, Operating, Gross Margins6IV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. 6IV.DE Health Analysis

2.1 Basic Checks

  • 6IV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for 6IV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
6IV.DE Yearly Shares Outstanding6IV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
6IV.DE Yearly Total Debt VS Total Assets6IV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • 6IV has an Altman-Z score of -1.36. This is a bad value and indicates that 6IV is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -1.36, 6IV is not doing good in the industry: 69.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.36
ROIC/WACCN/A
WACC7.84%
6IV.DE Yearly LT Debt VS Equity VS FCF6IV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 2.96 indicates that 6IV has no problem at all paying its short term obligations.
  • 6IV has a better Current ratio (2.96) than 61.73% of its industry peers.
  • 6IV has a Quick Ratio of 2.96. This indicates that 6IV is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 2.96, 6IV is doing good in the industry, outperforming 64.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
6IV.DE Yearly Current Assets VS Current Liabilites6IV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. 6IV.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.23% over the past year.
  • Looking at the last year, 6IV shows a very negative growth in Revenue. The Revenue has decreased by -51.26% in the last year.
  • The Revenue has been growing by 64.51% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)22.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.34%
Revenue 1Y (TTM)-51.26%
Revenue growth 3Y-28.33%
Revenue growth 5Y64.51%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, 6IV will show a very strong growth in Earnings Per Share. The EPS will grow by 30.08% on average per year.
  • Based on estimates for the next years, 6IV will show a very strong growth in Revenue. The Revenue will grow by 139.62% on average per year.
EPS Next Y40.18%
EPS Next 2Y12.1%
EPS Next 3Y17.02%
EPS Next 5Y30.08%
Revenue Next Year-73.92%
Revenue Next 2Y74.09%
Revenue Next 3Y145.04%
Revenue Next 5Y139.62%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
6IV.DE Yearly Revenue VS Estimates6IV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
6IV.DE Yearly EPS VS Estimates6IV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. 6IV.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • 6IV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 6IV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
6IV.DE Price Earnings VS Forward Price Earnings6IV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
6IV.DE Per share data6IV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as 6IV's earnings are expected to grow with 17.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.1%
EPS Next 3Y17.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 6IV.DE Dividend Analysis

5.1 Amount

  • 6IV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

6IV.DE Fundamentals: All Metrics, Ratios and Statistics

INVENTIVA SA

FRA:6IV (4/17/2026, 7:00:00 PM)

4.77

+0.14 (+3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-25
Inst Owners38.4%
Inst Owner ChangeN/A
Ins Owners4.48%
Ins Owner ChangeN/A
Market Cap990.78M
Revenue(TTM)4.48M
Net Income(TTM)-354.14M
Analysts88.75
Price Target13.27 (178.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.42%
PT rev (3m)9.12%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.93%
EPS NY rev (3m)7.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 221.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -197.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -1.36
F-ScoreN/A
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.34%
EPS Next Y40.18%
EPS Next 2Y12.1%
EPS Next 3Y17.02%
EPS Next 5Y30.08%
Revenue 1Y (TTM)-51.26%
Revenue growth 3Y-28.33%
Revenue growth 5Y64.51%
Sales Q2Q%-100%
Revenue Next Year-73.92%
Revenue Next 2Y74.09%
Revenue Next 3Y145.04%
Revenue Next 5Y139.62%
EBIT growth 1Y-30.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.54%
EBIT Next 3Y16.18%
EBIT Next 5Y35.44%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA / 6IV.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INVENTIVA SA?

ChartMill assigns a fundamental rating of 2 / 10 to 6IV.DE.


What is the valuation status of INVENTIVA SA (6IV.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (6IV.DE). This can be considered as Overvalued.


How profitable is INVENTIVA SA (6IV.DE) stock?

INVENTIVA SA (6IV.DE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for INVENTIVA SA?

The Earnings per Share (EPS) of INVENTIVA SA (6IV.DE) is expected to grow by 40.18% in the next year.